Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
MR Differential Diagnosis of Normal-Pressure Hydrocephalus and Alzheimer Disease:Significance of Perihippocampal Fissures
AJNR 19:813-819, Holodny,A.I.,et al, 1998
Demonstration of CSF Gamma-globulin Banding in Presenile Dementia
Neurol 30:882-884, Williams,A.,et al, 1980
Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimers Disease Neuroimaging Initiative
AJNR 36:653-660, Chow, N.,et al, 2015
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Neurodegenerative causes of death among retired National Football League Players
Neurol 79:1970-1974, Lehman, E.,et al, 2012
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging
JAMA 302:2565-2572, 2593, Lieb,W.,et al, 2009
Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Alzheimers Disease
AJNR 30:578-580, Brewer, J.B.,et al, 2009
Functional Magnetic Resonance Imaging in Neuropsychiatry
BMJ 319:1551-1554, Longworth,C.,et al, 1999
Low Body Weight in Alzheimer's Disease is Associated with Mesial Temporal Cortex Atrophy
Neurol 46:1585-1591, Grundman,M.,et al, 1996
Prospective CT Confirms Differnces Between Vascular and Alzheimer's Dementia
Stroke 26:735-742, Meyer,J.S.,et al, 1995
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
End-State Alzheimer's Disease:Glasgow Coma Scale and the Neurologic Examination
Arch Neurol 50:1309-1315, Benesch,C.G.,et al, 1993
Assessing the Severity of Dementia:Patient and Caregiver
Arch Neurol 48:274-277, Tuenisse,S.,et al, 1991
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment
JAMA Neurol 81:845-856, Groot,C.,et al, 2024
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Outcomes after Diagnosis of Mild Cognitive Impairment in a Large Autopsy Series
Ann Neurol 81:549-559, Abner, E.L.,et al, 2017
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
CSF biomarkers in posterior cortical atrophy
Neurol 76:1782-1788, Seguin, J.et al, 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Age, Neuropathology, and Dementia
NEJM 360:2302-2309, Savva,G.M.,et al, 2009
CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
The Clinical Course of Advanced Dementia
NEJM 361:1529-1538, 1595, Mitchell,S.,et al, 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Survival Times in People with Dementia: Analysis From Population Based Cohort Study With 14 Year Follow-Up
BMJ 336:258-262,225, Xie,J.,et al, 2008
Prodromal Alzheimers Disease: Successive Emergence of the Clinical Symptoms
Ann Neurol 64:492-498,479, Amieva,H.,et al, 2008
Incident Dementia in Women is Preceded by Weight Loss by a Least a Decade
Neurol 69:739-746, Knopman,D.S.,et al, 2007
Mild Cognitive Impariment is Early-Stage Alzheimer Disease
Arch Neurol 63:15-16, Morris,J.C., 2006